Purpose: Percutaneous ablation techniques, including microwave ablation (MWA) and radiofrequency ablation (RFA), have become important minimally invasive treatment options for liver cancer. This systematic review compared MWA with RFA for treatment of liver cancer. Methods: The systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic search of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials was conducted for randomized and observational studies published from 2006 onwards. A random-effects model was used for meta-analyses and local tumor progression (LTP), technique efficacy, overall survival (OS), disease-free survival (DFS), intrahepatic de novo lesions (IDL), extrahepatic metastases (EHM), length of stay (LOS), and complications were analyzed. Subgroup and sensitivity analyses were also conducted. Results: Of 1379 studies identified, 28 randomized and observational studies met inclusion criteria. The main analysis demonstrated that LTP was significantly reduced by 30% with MWA versus RFA (RR=0.70; P=0.02) (all studies) and by 45% with MWA versus RFA (RR=0.55; P=0.007) (randomized studies only). There were no significant differences between MWA and RFA for other efficacy and safety outcomes. Higher frequency (2450 MHz) and larger tumor size (≥2.5 cm) are amongst variables that may be associated with improved outcomes for MWA. Sensitivity analyses were generally congruent with the main results. Conclusion: MWA is at least as safe and effective as RFA for treating liver cancer and demonstrated significantly reduced LTP rates. Future studies should assess time and costs associated with these two treatment modalities. Keywords: microwave ablation, radiofrequency ablation, hepatocellular carcinoma, metaanalysis, liver cancer
Introduction
Primary liver cancer is the second leading cause of cancer-related deaths and accounted for 788,000 mortalities in 2015. 1 Surgical resection is considered the gold standard of treatment for curative intent but is often only possible in the early stages of hepatocellular carcinoma (HCC) and among those with limited cirrhosis. 2 During the past ten years, percutaneous ablation has become an important minimally invasive alternative to surgery for liver cancer. 3 Radiofrequency ablation (RFA) is currently the most widely used thermal ablation modality for unresectable, early-stage, hepatic malignancy. 2 Microwave ablation (MWA), which was first introduced in 1994, 4 has recently increased in use as a result of several significant advancements in the technology and improvements in the clinical application. These advancements include improvements in microwave applicator tissue attachment, spatially and synchronously distributed power to multiple antennas, 5, 6 and the development of internally cooled applicators with distal energy control. [7] [8] [9] The primary clinical advantages these advancements in MWA have provided are higher temperatures and faster heating than RFA, shorter ablation times, larger ablation volumes, and less heat sink effect. 8 Although MWA and RFA both destroy tissue via thermally induced coagulative necrosis and the frequencies of microwaves used in MWA are from the radiofrequency spectrum, 10 the two ablative modalities differ in their mechanisms of energy deposition.
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RFA has limited effectiveness in tissues with low electrical conductivity (eg adipose tissue) 8 since it requires an electrically conductive route through which to transfer resistive heat. RFA applies frequencies from 450 to 500 kHz to destroy tissues in the proximity of the electrode by causing friction that results in heating. The heating produced by RFA is maintained from 50°C to 100°C to avoid charring the tissue and rendering it electrically non conductive. 8, 11 Charred tissue acts as an insulator that prevents radiofrequency energy transfer to surrounding tissue, thus limiting ablation volumes. The optimal protocols for maximizing RFA ablation volumes involve using slow and methodical energy deposition. In contrast, MWA applies an electromagnetic field of either 915 or 2450 MHz to the tissue surrounding the antenna, heating it to >150°C via dielectric polarization 11 and is most effective in tissues with high water content. 8 The MWA direct heating mechanism leads to larger, more homogenous ablation zones than RFA, that are created more quickly. 8, 12 MWA is less susceptible to the heat sink effect 11, 13, 14 which is the dissipation of heat via blood vessel perfusion. 11, 12 Reduced heat sink effect susceptibility may enable MWA to produce larger ablation zones. Larger and more uniform ablation zones with MWA may destroy neoplastic cells more effectively compared with RFA, potentially impacting local tumor progression (LTP). Meta-analyses have compared MWA with RFA for the treatment of HCC. [15] [16] [17] [18] Generally, these studies have shown similar efficacy and safety between these modalities, with some benefit in LTP for MWA in larger hepatic tumors. 17, 18 However, several clinical studies, not included within these meta-analyses, have been published recently. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Moreover, these meta-analyses have been limited by the type and number of outcomes included. The aim of this meta-analysis is to compare the efficacy and safety of MWA to RFA for the treatment of patients with HCC or liver metastasis. The meta-analysis included both randomized and observational studies; the outcomes were the rate of LTP, technique efficacy, overall survival (OS), disease-free survival (DFS), intrahepatic de novo lesions (IDL), extrahepatic metastasis (EHM), length of stay (LOS), and complications.
Methods

Search strategy
This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 30 A systematic search of MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials was conducted for systematic reviews, randomized controlled trials (RCTs), and observational studies (prospective or retrospective cohort and case-control studies) using a search strategy developed by a medical information specialist that involved controlled vocabulary and keywords related to our research question (eg, "Liver Neoplasms", "Microwave", "Ablation Techniques") (Appendix A). The search strategy was not limited by time or language; however, only English language articles published on or after January 1, 2006, were screened. The strategy was peer-reviewed by another senior information specialist prior to execution using the PRESS Checklist. 31 Searches for the systematic reviews and RCTs were performed on October 29, 2017 . A supplementary search for non-RCTs was performed on November 24, 2017. Reference lists of retrieved articles and relevant reviews were handsearched. As this meta-analysis examined existing data from published studies, it was exempted from Institutional Review Board (IRB) approval.
Study selection
Specific inclusion criteria were defined according to PICOS (ie, population, intervention, comparator, outcomes, and study design). Studies were considered for inclusion in the meta-analysis if they were RCTs or observational studies comparing MWA with RFA in adults (≥18 years) with confirmed HCC or liver metastasis who either refused or were ineligible for surgery. Based on the inclusion criteria, the eligibility of each publication was evaluated in the title and abstract review. If the title and abstract suggested potential eligibility, a full-text screening followed. Reviewers were not blinded to the names of the authors or the institutions of the studies considered for inclusion, but no criteria were applied to include or exclude studies based on these parameters. Systematic reviews and meta-analyses were reviewed for insight and reference retrieval. Articles published before January 1, 2006, were excluded given the high likelihood that outdated technologies were used. Records were evaluated for eligibility by two independent reviewers and discrepancies were resolved either through consensus or by adjudication from a third reviewer.
Data extraction
Details (ie, baseline characteristics and outcomes) from the included studies were extracted using a standardized data extraction form developed in Microsoft Excel. The following study details were retrieved: study authors, publication year, study time frame, study design, country of origin, sample size, key patient characteristics (eg, age, diagnosis, average tumor size, average number of ablated tumors, duration of follow-up, etc.), intervention and comparator details [eg, microwave system, frequency, utilization of transarterial chemoembolization (TACE), transarterial embolization (TAE) etc.], and detailed outcomes data. Some studies did not report percentages in text for LTP, OS, and DFS, but did present Kaplan-Meier curves, which were utilized instead (extracted using DigitizeIt 2.2.2, Braunschweig, Germany). If studies did not report the number at risk at each time point, the denominator for number treated was assumed to be the initial sample size. Data were extracted by one reviewer and then checked for accuracy by a second reviewer with discrepancies resolved by consensus, or by adjudication from a third reviewer.
Study outcomes
LTP was defined as reappearance of tumors within or adjacent areas to the ablation zone. 10 This definition aligned with many study definitions of "local recurrence". If a study reported "recurrence" but did not specify whether it was local or distant, it was assumed to be local (only two studies). 21, 32 If more than one LTP value was reported, the latest value in the study was used in the meta-analysis. Other outcomes were 1) technique efficacy (typically defined as complete tumor ablation), measured at one week to three months post ablation; 10 2) one-, three-, and five-year OS; 3) one-, three-, and five-year DFS; 4) IDL, defined as appearance of a new tumor at a new focus within liver (sometimes referred to in studies as "de novo lesions," "intrahepatic metastasis," or "distant recurrence"); 5) EHM, defined as appearance of a new tumor outside the liver; 6) length of hospital stay (days); and 7) overall complications, including any major or minor adverse events that were reported by the studies. For outcomes that were not typically measured at defined time points within the study (ie, LTP, IDL, EHM, and complications), study data were excluded if the study reported a large difference in mean follow-up time (ie, ≥25% difference) between treatment arms.
Risk of bias assessment
The quality of studies included in the meta-analyses was assessed using the Cochrane Risk of Bias (RoB) tool 33 for
RCTs and the Newcastle-Ottawa quality assessment Scale (NOS) 34 for observational studies. The RoB tool assessed the following domains: sequence generation, allocation concealment, blinding, selective reporting, and other sources of bias. Each study was assigned a rating for each domain (ie, low, unclear, or high risk of bias). The NOS assessed the following categories: selection (ie, representativeness of exposed cohort, selection of nonexposed cohort, ascertainment of exposure, demonstration that the outcome of interest was not present at the start of the study), comparability (comparability based on design and analysis), and outcome (assessment of the outcome, follow-up long enough for the outcome to occur, and adequacy of follow-up of cohorts). When assessing cohort representativeness, the studies received a star if they were representative of the HCC population: BCLC stage 0 or A (Child-Pugh A or B, single tumor ≤3 cm, or up to three nodules ≤3 cm). 2 For studies of liver metastasis, no restrictions were placed on the source of the primary tumor. For comparability, studies received a star if treatment groups were balanced on the potential effect modifiers of ChildPugh class (HCC studies) and tumor size and primary origin (metastatic studies). Studies also received a star if they used a matching design, or regression analyses indicated that Child-Pugh class or tumor size and primary origin were not predictors of outcomes. Studies received an additional star if they were balanced on additional potential effect modifiers [ie, age, gender, tumor size (for HCC), surgical approach, tumor location], or they used a matching design, or regression analyses indicated that these variables were not predictors of outcomes. For outcome assessment, a study received a star if the follow-up time was at least six months. Studies also received a star if loss to follow-up was less than 20%. 33 In total, each observational study could obtain a maximum of nine stars. The quality of included studies was assessed by two reviewers and reconciled by a third reviewer, if required.
Data synthesis and statistical methods
The DerSimonian-Laird random-effects model was used for the meta-analyses and forest plots were generated. For continuous outcomes (ie, LOS), the weighted mean difference (WMD) and its corresponding 95% CI were calculated. For dichotomous outcomes (all outcomes except LOS), the relative risk (RR) and the corresponding 95% CIs were calculated. As follow-up times varied across studies, a random-effects metaregression analysis was completed to assess the association between mean study follow-up time and the treatment effect for LTP. All analyses were conducted for RCTs alone, observational studies alone, and the combination of RCTs and observational studies. An I 2 value was generated to describe the percentage of variance attributable to heterogeneity among studies. 33 The following ranges were used to interpret I 2 values: 0-40%
represented minimal heterogeneity, 30-60% represented moderate heterogeneity, 50-90% represented substantial heterogeneity, and 75-90% represented considerable heterogeneity. 33 The following subgroup analyses were conducted for LTP, one-year OS, complications, and technique efficacy outcomes: 1) tumor size (<2.5 versus ≥2.5 cm); 2) type of liver tumor (HCC versus metastasis); 3) impact of adding another treatment to both arms (MWA and RFA versus MWA+TACE and RFA+TACE); and 4) MWA frequency (915 versus 2450 MHz). For the subgroup analysis assessing the effects of the type of liver tumor, any study that included patients with metastatic tumors was classified as a metastatic study. Additionally, several sensitivity analyses were performed to assess the impact of alternative methods (ie, fixed-effects model), study quality (ie, exclusion of lower quality studies, defined as any RCT with high risk for any domain of the RoB tool or any observational study with ≤7 stars on the NOS), and surgery type (ie, exclusion of open surgical approach). Publication bias was examined using funnel plots for outcomes reported by 10 or more studies. 35 Data were analyzed using STATA (Version 15.1, Texas, USA).
Results
A total of 1379 citations were identified from database searching. After removing duplicates, 1137 unique records were screened. Of these, 1064 studies were excluded at the abstract screening phase for several reasons (eg, non-human, not English, not liver cancer, etc.) (Figure 1 56 and geography. 57 Study characteristics are presented in Table 1 . The sample size of the included studies (four RCTs and 24 observational studies) ranged from 19 to 460 patients and study follow-up duration ranged from five to 62 months. The average age across studies ranged from 50.4 to 69.4 years. In total, most studies (n=10) originated from China. Other regions included USA (n=7), Egypt (n=3), Italy (n=3), Japan (n=2), Australia (n=1), Belgium (n=1), and the Netherlands (n=1). Retreatment after the initial ablation session was reported by 16 studies (Table S1) Quality assessment
RCTs
Risk of bias assessments and individual study quality assessments are presented in Table S2 and Figure S1 . Overall, the quality of studies was acceptable, with most studies having low or unclear risk of bias across most domains. Two studies reported the methods for random sequence generation (ie, coin flip and computer-generated) 40, 41 and the other two studies 20, 21 were assigned an unclear risk of selection bias as no information was provided. The methods for allocation concealment were defined by one study (centralized computer-generated allocation list) 41 and the other three studies 20, 21, 40 were assigned an unclear risk of selection bias. The risk of bias associated with blinding of patients or outcome assessors was considered to be low for outcomes because of their objectivity. For three studies, patient withdrawals, loss to follow-up, and missing data were minimal. However, one study reported a loss to follow-up of greater than 20% and was assigned high risk for attrition bias due to incomplete OS data. 40 The bias associated with selective reporting was unclear for all studies.
Observational studies
The NOS scores for observational studies are presented in Table S3 . The 24 observational studies were given scores that ranged from 7 to 9; the studies varied in terms of comparability and adequacy of follow-up. All studies were either truly or somewhat representative of the exposed cohort, drew the non exposed cohort from the same community as the exposed cohort, and used secure records for exposure ascertainment. Most studies received two stars for comparability; however, seven studies received one star as they did not report Child-Pugh classification, 24, 51 or reported differences in patient age, sex, ablation approach, tumor size, or primary origin between treatment arms. These variables were either not controlled for, or adjusted analyses showed that one or more of them affected outcomes. 23, 25, 28, 47, 53 Only one study received no stars for comparability because it did not report Child-Pugh classification and reported significant differences between treatment arms for patient age and tumor size. 32 Additionally, one study did not receive a star for the adequacy of the follow-up period as it did not report the follow-up time for the RFA group. 47 There were no studies that had a loss to follow-up that could potentially impact results (ie, >20%). Overall survival Based on sample size, weighted averages demonstrated that OS at three years (77% versus 73%) and five years (63% versus 59%) was higher with MWA compared with RFA, respectively (Figure 3 ), although the meta-analyses indicated no significant differences [one-year OS (RR=1.00; P=0.80), three-year OS (RR=1.03; P=0.40), and five-year Figure 4 , Figure S3 -S5).
Analysis LTP
DFS
Similar to OS, weighted averages showed that DFS at one year (83% versus 81%), three years (57% versus 51%), and five years (39% versus 34%) was higher with MWA as compared with RFA ( Figure 3) ; however, the meta-analysis indicated these differences were not statistically significant [one-year (RR=1.00; P=0.93), three-year (RR=1.05; P=0.27), and five-year (RR=0.97; P=0.86) DFS] ( Table 2 , Figure 4 , Figure S6 -S8). Figure 4 , Figure S9 -S10).
IDL and EHM
LOS
Although not statistically significant, LOS was lower by 0.4 days with MWA compared with RFA based on seven observational studies (WMD=−0.40 days; P=0.26) ( Table 2 , Figure S11 ). Figure 4 , Figure S12 ).
Overall complications
Subgroup analyses
Tumor size (<2.5 versus >2.5 cm) Results showed that there were no statistically significant differences between MWA and RFA regardless of tumor size for one-year OS, complications, and technique efficacy outcomes (Table 3) . However, for the outcome of LTP, MWA was associated with a significant reduction of 37% (RR=0.63; P=0.001) compared with RFA, among patients with tumor sizes ≥2.5 cm (Table 3) .
Type of tumor (HCC versus metastasis)
No statistically significant differences were reported between MWA and RFA for complications and technique efficacy regardless of tumor type (Table 3) (Table 3 ).
Adding another treatment to both arms (MWA and RFA versus MWA + TACE and RFA + TACE) There were no significant differences between MWA and RFA for one-year OS, complications, and technique efficacy, regardless of whether TACE was added to ablation treatment arms or not. For LTP, MWA was associated with a lower risk compared with RFA for both comparisons; however, results were only significant for the comparison of MWA and RFA only (RR=0.72; P=0.02) ( Table 3) .
MWA frequency (915 versus 2450 MHz)
For the outcomes of one-year OS, complications, and technique efficacy, there were no significant differences between MWA and RFA, irrespective of MWA frequency. For LTP, the 2450 MHz MWA frequency was associated with a significant reduction of 33% compared with RFA (RR=0.67; P<0.001); however, the 915 MHz MWA frequency was associated with an increase in the risk of LTP (RR=1.79; P=0.01) ( Table 3) .
Sensitivity analyses
Results of sensitivity analyses on alternative methods (ie, fixed-effects model), study quality (ie, exclusion of poor-quality studies), and surgery type (ie, exclusion of studies involving open surgery 23, 25, 44 ) were similar in magnitude and direction to the main analysis with some exceptions. MWA was associated with a significant reduction in LTP for all sensitivity analyses. Additionally, when fixed-effects models were used instead of the random-effects model, MWA was associated with significant improvements in technique efficacy (RR=1.02; P=0.04), reductions in EHM (RR=0.64; P<0.05), and hospital LOS (WMD=−0.27 days; P<0.05) compared with RFA. The results of the meta-analysis were not sensitive to the exclusion of studies involving open surgery (Table 4) .
Publication bias
Outcomes reported by ≥10 studies (LTP, technique efficacy, one-and three-year OS, and complications) were examined for publication bias using funnel plots. Results demonstrated a low risk of publication bias for the outcomes assessed. The funnel plot for LTP is presented in Figure 5 , and those for technique efficacy, one-and threeyear OS, and complications are presented in Figure S13 .
Discussion
This study represents, to the authors' knowledge, the first documentation of statistically significant improvements in LTP for patients with liver tumors treated with MWA in comparison to RFA based on the analysis of 3531 patients in 28 studies. Specifically, the risk of LTP was significantly reduced by 30% with MWA compared with RFA when analyzing all included studies. Furthermore, if only the three RCTs are considered, the LTP was significantly reduced by 45%. Additional analyses were performed using the fixed-effects model, with exclusion of poor-quality studies, and those using an open surgical approach for ablation. These analyses demonstrated results that were congruent with the main analyses. OS and DFS were not significantly different between the MWA and RFA treatment arms. This finding is not unexpected given the presence of underlying liver disease in the HCC population and the multimodal therapy required for colorectal liver metastasis. In fact, LTP is generally considered a better indicator of treatment effectiveness for ablative therapies than OS or DFS because of the aforementioned factors. There was one notable exception, in that one-year OS significantly favored RFA over MWA in patients with metastatic disease. This effect is driven by the results from the van Tilborg et al, 2016 study, in which patients were assigned to MWA based on tumor proximity to blood vessels or to RFA based on tumor proximity to the biliary tract, diaphragm, or intestine. 25 This allocation bias may have affected our results. In addition to the current metaanalysis, Huo performed a subgroup analysis on tumor type (HCC and metastases) and found conflicting results. 16 Notably, only a few studies were included in metastases populations; thus, future studies are required to further assess this subgroup effect.
Results of the subgroup analyses indicated significant differences between treatment modalities based on tumor size and tumor type. LTP was the same between MWA and RFA for tumors less than 2.5 cm, but MWA had a significant reduction of 37% in LTP when compared with RFA in tumors ≥2.5 cm. This finding is consistent with a previous meta-analysis (discussed below). 18 This is also consistent with the physics of radiofrequency and microwave energies. The penetration with RFA is variable because of the heat sink effect and the insulative effect of charred tissue. 8, 11, 58 MWA will achieve penetration of 2.0 cm, leading to larger ablation volumes than RFA. 8 Thus, tumors approximately 2.0 cm in diameter should be adequately covered with margin if the tumor is precisely targeted in the center and the margin is kept to 5 mm, as is the case for HCC. Conversely, the advantages of MWA should be observed for tumors greater than 2-2.5 cm because of the greater tissue penetration. These findings raise the question of whether the overall significant results seen for LTP with MWA over RFA are solely the result of the large tumor effect. However, the present study does not completely exclude a benefit of MWA for smaller tumors since a nonsignificant reduction of 28% was observed for tumors less than 2.5 cm. Despite the overall improvement in LTP for MWA over RFA, the risk of complications was not significantly different between groups. This finding is important since larger ablations could be perceived to have a higher risk of complications. The results of this study refute that viewpoint. Technical efficacy was also not significantly different between MWA and RFA, nor for any subgroup analysis. This result is not surprising given the limitations associated with measurement of technique efficacy by the inability of imaging to detect whether neoplastic cells within the ablation zone have been sufficiently ablated, 11 by variability between assessors in such evaluations, the high rates (>80%) reported for techniques efficacy in both arms, and by continuing ablation until an adequate margin is determined. Unfortunately, this analysis was unable to assess the number of treatment courses per procedure to achieve similar technique efficacy in both treatment arms. However, in the RCT performed by Yu et al, the number of treatment courses per session (or procedure) was significantly lower in the MWA treatment arm versus the RFA arm. 20 This suggests that despite similar technical efficacy rates, MWA is more efficient than RFA. Three systematic reviews and meta-analyses have recently been published of the comparison between MWA and RFA for the treatment of HCC and/or liver metastases. 15, 16, 18 Huo and colleagues included metastatic liver cancer studies, 16 whereas they were not included by Luo and Facciorusso. Luo found that MWA and RFA had similar rates of one-and three-year survival, complete tumor ablation, local tumor recurrence, and major complications, 15 which generally aligns with the results reported here. Huo and colleagues reported similar findings in their meta-analysis of both HCC and metastatic patients. 16 However, our meta-analysis showed that MWA was also associated with significantly lower LTP compared with RFA. In comparison to these two systematic reviews, the current meta-analysis included several additional studies. Facciorusso and colleagues, 18 whose findings were generally aligned with the other two published reviews, included only seven studies in their meta-analysis (two RCTs and 5 observational studies) and only five were in common with the 28 included in our study. 32, 40, 45, 50, 55 Regarding local recurrence, Facciorusso reported significantly lower odds with MWA over RFA (OR=0.46; P=0.02) in patients with high tumor burden (>1.2 tumors per patient and/or large tumors >2.5 cm in diameter).
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This meta-analysis had broad inclusion criteria allowing for a wide variety of subgroup analyses other than tumor size and type. The results of the frequency subgroup analysis showed that the benefit of MWA over RFA was most apparent for the 2450 MHz versus the 915 MHz frequency. These results may be explained by the ability of 2450 MHz MWA systems to deliver greater amounts of power and achieve larger ablation volumes. 11 A recent observational study comparing 915 and 2450 MHz MWA for ablation of lung metastases found that ablation margin size was significantly associated with the local progression rate and that 2450 MHz MWA demonstrated a significantly better local progression-free survival curve than 915 MHz MWA (P=0.048). 59 Liu and colleagues did not report any differences in treatment effect when comparing these two MWA frequencies. 60 The results of the tumor type subgroup analysis on HCC and metastases showed that there were no differences between MWA and RFA in HCC or metastases for technique efficacy and complications.
There are a few limitations of this meta-analysis. First, most of the included studies are observational (primarily retrospective cohort studies) and present a potential for selection bias. RFA was often used for a longer time at institutions than MWA and had a longer follow-up duration than MWA. Despite this, most studies were well balanced for baseline covariates, and some of the studies used matching to control for differences or reported regression analyses that showed the minimal impact of potential effect modifiers on treatment outcome. To control for the effect of poor study quality, studies receiving lower quality assessment scores were excluded in a sensitivity analysis. The results of these sensitivity analyses remained aligned with the main analyses. Second, there was often variability between and within studies for follow-up time; this was handled in two ways: 1) a meta-regression was performed to determine whether follow-up time had a significant effect on LTP (results showed there was no effect) and 2) studies with ≥25% difference in mean follow-up time between arms were excluded from analyses of outcomes potentially impacted by follow-up time. Third, significant heterogeneity was observed for certain outcomes, such as five-year DFS and LOS, which may have been due to variability in patient baseline characteristics, treatment parameters, and study designs across studies. As such, random-effects model, which accounts for heterogeneity, was used; sensitivity analyses were performed with a fixed-effects model. Fourth, due to the broad inclusion of this meta-analysis, there was some variability in the definitions of outcomes, particularly technique efficacy and LTP. Reporting guidelines recommend that technique efficacy (often called complete tumor ablation or complete response) should be assessed by imaging ideally one week to one month after the procedure and no later than three months afterwards. 10 Thus, studies were included regardless of the terminology used to describe the outcome, as long as it was reported from one week to three months after treatment. It is unclear whether all the studies assessed treatment efficacy (ie, effective ablation of tumors) or if some assessed technical success (ie, tumors treated according to protocol), 10 since these terms are sometimes used interchangeably. As well, the terminology used to define local tumor recurrence or LTP were sometimes variable. Here, we used the following definition for LTP: reappearance of tumors, within or adjacent to the ablation zone, based on that of Ahmed et al. 10 This definition often allowed the inclusion of studies which DovePress labeled the outcome as LTP and studies which labeled it as local tumor recurrence (LTR). However, it is unclear whether minor variations in definition could have impacted overall results. Finally, 16 studies reported that patients underwent retreatment after initial ablation; however, it is difficult to assess how retreatment could have impacted outcomes due to lack of data availability (ie, outcomes were not reported separately for patients that did or did not receive retreatment or by type of retreatment). Despite these limitations, this meta-analysis is strengthened by its broad inclusion of 28 studies in liver cancer which enrolled over 3500 patients. The time period for study inclusion was limited from 2006 to 2017 to control for the use of outdated ablation devices. A broad range of outcomes such as IDL and EHM were included, which have not been meta-analyzed previously. This meta-analysis also used several methods to control for heterogeneity and study quality including use of a random-effects model, subgroup and sensitivity analyses, study quality assessment, assessment of publication bias, and meta-regression analysis.
Conclusions
In conclusion, results indicated that MWA is just as safe and effective as RFA for the treatment of HCC or liver metastases. Compared with RFA, MWA is associated with statistically significantly lower rates of LTP across analyses. Subgroup analyses showed that higher frequency (ie, 2450 MHz MWA) and larger tumor size (ie, >2.5 cm) may be associated with improved outcomes for MWA versus RFA. Further studies are required to assess the cost and time savings associated with MWA versus RFA as well as the comparison of MWA with non ablative strategies (eg, resection).
Data availability
The dataset supporting the conclusions of this article is included in the article (and its supplementary data).
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